Discuss how we can help with your business location or expansion requirementsGet in touch
The Queen Elizabeth Hospital Birmingham (QEHB) is run by University Hospitals Birmingham NHS Foundation Trust (UHB), and is recognised as one of the leading hospitals in Europe with an international reputation for quality of care, informatics, clinical training and research. QEHB provides direct clinical services to nearly 800,000 patients every year, serving a regional, national and international population.
Located within Greater Birmingham’s medical quarter, the Trust is surrounded by a number of leading-edge healthcare facilities all within close proximity. Clustered on a single site, the QEHB, The Institute of Translational Medicine, the University of Birmingham Medical School and Birmingham Women’s Hospital make this healthcare campus one of the largest in the world. Further life science experts continue to invest in and around the site, taking advantage of one of the UK’s most diverse patient populations and unrivalled patient catchment areas offered in Greater Birmingham.
The Trust is a national centre of excellence for cancer, trauma, renal dialysis, burns and plastics, and has the largest solid organ transplantation programme in Europe. As a result of its clinical expertise in treating trauma patients and military casualties, QEHB has been designated both a Level 1 Trauma Centre and host of the UK’s only £20m National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre (SRMRC).
Safe Patient Systems solves clinical problems by creating simple and patient centric mobile solutions, designed by clinicians that harness technology to enable more efficient healthcare and improved patient outcomes.
Born out of the Research and Development department of one of the UK’s leading NHS Trusts, Heart of England NHS Foundation Trust, the company shares many of the values of the NHS around how it prioritises patients, listens, learns and develops evidence-based solutions.
When moving from its existing base at Heartlands hospital, Solihull was a first choice largely due the prestigious location and great transport links. The motorway provides easy access to the South East where a large number of technology partners are based.
The Centre for Rare Diseases at the Queen Elizabeth Hospital Birmingham offers a unique care hub to the patients it serves. Opened in September 2015, it has since seen around 2,000 patient appointments, with thirty four bespoke clinics integrating expert, multi-specialty care with research. The facility forms part of the NIHR Clinical Research Facility within the Institute of Translational Medicine.
The rare disease centre’s focus is on highly organised, one-stop clinics where patients, supported by their carers, undergo pre-planned diagnostic tests and see all the relevant specialists and the multi-disciplinary team in one visit. Working alongside the centre, the West Midlands Genomics Medicine Centre (WMGMC) is one of thirteen such centres in England delivering the 100,000 Genomes Project.
The WMGMC project complements the work within the rare disease centre and ensures the Trust is leading the way in improving the prediction and prevention of disease, enabling more new and precise diagnostic tests and allowing personalisation of drugs and other treatments to specific genetic variants to benefit generations to come.
Dr Graham Lipkin, Consultant Nephrologist and lead for the centre, said:
“Many people in the UK are living with a rare disease, which can have a major impact on the quality of their life and on their close relatives. There are an estimated 7000 rare diseases and most of these are inherited. The centre works with our patients, staff and partners to coordinate input from the large number of medical, nursing and therapy specialists that are generally required to provide the best level of care for people living with these conditions.”
The primary function of the Royal Centre for Defence Medicine (RCDM) is to provide medical support to military operational deployments. It also provides secondary and specialist care for members of the armed forces. It is a dedicated training centre for defence personnel and a focus for medical research.
The RCDM is based at the new Queen Elizabeth Hospital Birmingham, with defence personnel fully integrated with NHS staff to treat both military and civilian patients. The Trust also holds the contract for providing medical services to military personnel evacuated from overseas via the “Aero med service”.
RCDM Clinical Unit is the primary receiving unit for all military patients. In addition to operational casualties, RCDM accept non-operational casualties from around the world and referrals from around the UK. The hospital is at the leading edge in the medical care of polytrauma injuries. The experience gained by its staff working in this busy acute care environment provides the ideal training required for operations in Afghanistan and develops improved practice across the whole NHS.
The West Midlands Academic Health Science Network (WMAHSN) drives collaboration and productivity between academia, industry, healthcare providers and local citizens.
Through fostering a collaborative environment and supporting organisations across the region, the WMAHSN ensures Greater Birmingham’s life science community is fully integrated and demonstrating an internationally renowned competitive advantage. Through its networks, the WMAHSN accelerates the pace and scale of technology-led innovation to generate continuous improvement to the region’s businesses and its health economy.
WMAHSN helps start-ups and SMEs access funding and finance opportunities, find potential investors and locate international opportunities. WMAHSN also offers expert specialist advice and practical tools and techniques to help companies access new markets; aiding engagement with stakeholders and helping them understand and respond to clients’ needs. It also offers access to research and evaluation, with collaborative networks disseminating evidence to encourage uptake of ideas and collaboration amongst local businesses.
Professor Michael Sheppard, Chair of the WMAHSN, said:
“Accelerating patient access to new innovative medicines and technologies is at the heart of the life sciences sector in Greater Birmingham. The region’s unique infrastructure offers an integrated research and innovation platform that spans discovery, development, and implementation into clinical practice and ultimately evaluation. Birmingham is one of very few cities that can translate discoveries made in the laboratory into clinical practice at such pace, with a scale and efficiency that is unrivalled in the UK.”